Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

New real-world data confirms efficacy and safety of Pepaxti

September 1, 2025 – Two real-world studies from Spain and Italy presented at IMS 2025 show strong efficacy and favorable tolerability of Pepaxti in heavily pretreated multiple myeloma patients.

Read more

Information for investors

Oncopeptides recently decided to carry out a fully guaranteed new share issue of approximately SEK 150 million with preferential rights for the company’s existing ordinary shareholders.

Read press releases, other information and Q&A for investors

CEO Sofia Heigis - Oncopeptides AB

Released August 21, 2025

Oncopeptides publishes Q2 report 2025

Read report

Download

“Third consecutive quarter over quarter double-digit sales growth, 135 percent year over year”

CEO Sofia Heigis

 

See the Webcast

The presentation in PDF

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q3 2025 will be published November 5, 2025

Company news

Notice to Annual General Meeting at Oncopeptides AB (publ)

April 16, 2025

The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.

Read more

Oncopeptalks – first order in Italy and Q4 report

March 13, 2025

In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.

Read more

Oncopeptides receives first order of Pepaxti in Italy

March 11, 2025

Read more

Science news

New real-world data confirms efficacy and safety of Pepaxti

September 1, 2025

Two real-world studies from Spain and Italy presented at IMS 2025 show strong efficacy and favorable tolerability of Pepaxti in heavily pretreated multiple myeloma patients.

Read more

Oncopeptides announces acceptance of Spanish and Italian Real-World data at IMS Annual Meeting

July 23, 2025

Oncopeptides today announces that two real-world evidence (RWE) posters have been accepted for presentation at the upcoming International Myeloma Society (IMS) Annual Meeting, taking place in Toronto, Canada on September 17-20.

Read more

Oncopeptides launches new real-world evidence study of Pepaxti in Spain, first patient enrolled

May 20, 2025

Oncopeptides AB today announces that the first patient has been enrolled in its new real-world evidence study, evaluating the use of Pepaxti in routine clinical settings across Spain.

Read more

Investor news

CEO Sofia Heigis interviewed by Redeye

August 25, 2025

Redeye’s analyst Richard Ramanius interviews Sofia regarding the Q2 report 2025.

Read more

Investor Q&A: Oncopeptides Rights Issue and Japan Partnership

August 21, 2025

Read more about why Oncopeptides is carrying out a new share issue, how the funds raised, and what you as a current or potential shareholder should think about.

Read more

Invitation to presentation of the Q2 report 2025

August 14, 2025

Oncopeptides will publish the report for the second quarter 2025, at 08:00 CET on August 21, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on August 21 at 09:00 CET.

Read more

All Company news

All Science news

All Investor news

Press release - September 1, 2025

New real-world data confirms efficacy and safety of Pepaxti, presented at IMS Annual Meeting

Read press release

Latest press releases

All press releases

Upcoming events

2025-10-06 - 2025-11-04

Silent period

Other

2025-11-05

Interim Report Q3 202

Report

2026-01-19 - 2026-02-18

Silent period

Other

Full calendar
Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history

Released April 28, 2025

Oncopeptides publishes the 2024 Annual Report

Read report

Download

“2024 was a transformative year for Oncopeptides as we continued our journey toward sustainable growth and expanded access to Pepaxti.”

CEO Sofia Heigis

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025

Oncopeptides via e-mail